BBOT

BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibiting cell proliferation in KRAS-mutant cell lines BBO-11818 demonstrates robust anti-tumor activity as monotherapy and in combination across KRAS-mutant tumor models Updated Phase 1 clinical data are expected in the second half of 2026 SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today presented new preclinical data for BBO-11818, a selective, orally bioavailable non-covalent inhibitor that

Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development experience and scientific/business acumen to bear as the company's top executive Idan Elmelech, who previously served as Senior Vice President of Strategy & Business Development, will assume the position of Chief Operating Officer overseeing finance & accounting, corporate strategy, operations, and business development Neil Kumar, PhD, who played an integral role in the founding of BBOT as part of BridgeBio Pharma, Inc., has been appointed as Executive Chairman by the Board of Directors to guide t

BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed hyperglycemia BBO-10203 displays strong in vivo combination effects with HER2 inhibitors tucatinib or trastuzumab in HER2AMP models Updated clinical data are expected in the second half of 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today presented new preclinical data in an oral presentation for BBO-10203, a first-in-class covalent sma

BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 clinical data are expected in the second half of 2026 SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BBO-11818 for the treatment of adult patients with advanced KRAS-mutant pancreatic ductal adenocarcinoma. "Receiving Fast Track designation from the FDA for B

SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on April 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in March 2026. The employee received non-qualified stock options to purchase 32,675 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $8.40 per share, the closing price of BBOT's common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 on the first an

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 being held on April 17-22, 2026, in San Diego, California. The abstracts released today can be found on the AACR website here. Details on the presentations are as follows: Title: The RAS: PI3Kα breaker BBO-10203 inhibits PI3Kα/AKT activity in HER2+ models through non-canonical RAS signaling blockadeSession Category: Experimental and Molecular TherapeuticsSession Title:

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS mutant preclinical models, including KRASG12D and KRASG12V BBO-11818 showed significant tumor growth inhibition across multiple tumor types in preclinical models and demonstrated enhanced efficacy in combination with other anti-tumor agents, including BBO-10203, BBOT's selective RAS:PI3Kα breaker Preliminary clinical data from the BBO-11818 Phase 1 KONQUER-101 trial showed encouraging anti-tumor activities and differentiated safety, with additional data expected in the second half of 2026; interna

424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

10-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway.Announced encouraging preliminary safety and efficacy data across all three programs: BBO-8520's differentiated efficacy and safety profile as monotherapy and at active doses in combination with pembrolizumab with a potentially differentiated liver toxicity profile, BBO-11818 producing the first publicly disclosed partial response in PDAC as a panKRAS inhibitor, and BBO-10203 showing no hyperglycemia without HbA1c restriction — establishing the clinical foundation for differentiated combination strategies, including BBOT's intern

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in the upcoming months. Details of the company's participation are as follows: Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation: Wednesday, February 25, 2026, at 10:40 a.m. ET. Leerink Global Healthcare ConferencePresentation: Tuesday, March 10, 2026, at 10:00 a.m. ET. Live webcasts of the presentations will be accessible on the "Events" page of the BBOT website at h

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on February 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in January 2026. The employees received, in the aggregate, non-qualified stock options to purchase 65,350 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $10.84 per share, the closing price of BBOT's common stock as reported by Nasdaq on the effective date of the grant, which wil

Stifel initiated coverage of BridgeBio Oncology Therapeutics with a rating of Buy and set a new price target of $23.00

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on January 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of an individual hired by BBOT in December 2025. The employee received non-qualified stock options to purchase 129,090 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $13.19 per share, the closing price of BBOT's common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 on the f

Raymond James initiated coverage of BridgeBio Oncology Therapeutics with a rating of Outperform and set a new price target of $24.00

424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)